Buy Spiriva Respimat cartridge 2.5 mcg/dose, Respimat

Spiriva® [Tiotropium bromide]

Brand Boehringer Ingelheim

In stock 1554 Items

Available since: 2019-09-19

All payments are SSL encrypted
Full Refund if you haven't received your order
International shipping to the USA, UK and Europe

Clinical Pharmacology

Spiriva has an anticholinergic, bronchodilatory effect.

Indications

As maintenance therapy for patients with COPD, including chronic bronchitis and emphysema (with persistent dyspnea and to prevent exacerbations).

Composition

1 dose contains 2.5 mcg of tiotropium bromide.

Tiotropium bromide is marketed under different brands and generic names, and comes in different dosage forms:

Brand name	Manufacturer	Country	Dosage form
Spiriva Respimat	Boehringer Ingelheim	Austria	cartridge
Spiriva	Boehringer Ingelheim	Austria	capsules

No customer reviews for the moment.

Write your review

Dosage and Administration

The recommended dose of Spiriva Respimat is 2 inhalations (2 breaths) of an aerosol using the Respimat inhalation device.
Inhalation should be carried out 1 time per day at the same time.
Elderly patients can use Spiriva Respimat according to the recommended dose.
In patients with renal insufficiency, Spiriva Respimat may be used according to the recommended dose. The use of Spiriva Respimat, as well as other drugs that are mainly excreted by the kidneys, should be carried out under medical supervision in patients with moderate and severe renal insufficiency. In patients with hepatic insufficiency, the drug can be used according to the recommended dose.

Instructions for use
You should carefully follow these instructions.
Installing the cartridge and its preparation for use
Before first use it is necessary:
1. With the green cap closed, press the fuse and force out the transparent base.
2. Remove the cartridge from the box. Insert the narrow end of the cartridge into the inhaler until it clicks into place. The cartridge must be pressed gently against the hard surface to ensure that it is fully in place. Do not remove the cartridge after it has been installed in the inhaler.
3. Insert the transparent base into place. Do not remove the transparent base again.
To prepare the Spiriva Respimat inhaler for first use:
4. The inhaler Spiriva Respimat is held in its right hand with the green cap closed. Rotate the transparent base in the direction of the red arrows on the label until it clicks (half a turn).
5. Open the green cap until it opens completely.
6. Send the inhaler Spiriwa Respimat down. Press the button to release the dose. Close the green cap.
Repeat steps 4, 5 and 6 until an aerosol appears.
Then repeat 3 times the steps 4, 5 and 6 in order to make sure that the inhaler is ready for use.
Now inhaler Spiriva Respimat is ready for use.
These steps do not affect the number of available doses. After preparation, the inhaler Spiriva Respimat is designed for 30 doses (60 breaths).

Adverse reactions

Many of these adverse effects can be attributed to the anticholinergic properties of Spiriva Respimat.
Criteria for assessing the frequency of adverse drug reactions:> 10% - very often; 1–10% often; 0.1–1% - infrequently; 0.01–0.1% - rarely; On the part of metabolism, metabolism: the frequency is unknown - dehydration.
On the part of the nervous system: infrequently - dizziness; frequency unknown - insomnia.
From the organ of vision: infrequently - blurred vision; rarely - glaucoma, increased intraocular pressure.
Since the cardiovascular system: infrequently - atrial fibrillation, palpitations, supraventricular tachycardia, tachycardia.
On the part of the respiratory system: rarely - cough, nosebleeds, pharyngitis, dysphonia; rarely - bronchospasm, laryngitis; frequency unknown - sinusitis.
From the digestive tract: often - dry mouth, usually moderate; infrequently - constipation, oropharyngeal candidiasis, dysphagia; rarely - GERD, gingivitis, glossitis, stomatitis; frequency is unknown - intestinal obstruction, including paralytic intestinal obstruction.
On the part of the skin and immune system: infrequently - rash, itching; rarely - angioedema, urticaria, skin infections and skin ulcers, dry skin; frequency unknown - hypersensitivity (including immediate-type allergic reactions).
On the part of the musculoskeletal system and connective tissue: the frequency is unknown - swelling of the joints.
From the urinary system: infrequently - urinary retention (usually in predisposed men), urination disorders; rarely, urinary tract infection.

Contraindications

Hypersensitivity (includingto atropine or its derivatives, for example, ipratropium or oxitropium), I trimester of pregnancy, age up to 18 years.

Drug interactions

Despite the fact that special studies of interaction with other drugs were not performed, tiotropium bromide was used simultaneously with other drugs (sympathomimetic bronchodilators, methylxanthines, oral and inhaled steroids, which are used in the treatment of COPD) without adverse reactions. The study of the constant simultaneous use of tiotropium bromide with other anticholinergic drugs was not performed. Moreover, the constant simultaneous use of anticholinergic drugs with Spiriva Respimat is not recommended.

Pregnancy and Lactation

There are no clinical data on the safety and efficacy of using Spiriva® Respimat® during pregnancy.
In preclinical studies, no indications of direct or indirect adverse effects on pregnancy, embryo / fetus development, childbirth, or postnatal development have been obtained.
There are no clinical data on the safety and efficacy of tiotropium bromide during breastfeeding.
Spiriva Respimat should not be used in pregnant or lactating women, unless the potential benefit to the mother outweighs the potential risk to the fetus and child. For the period of use of the drug it is necessary to stop breastfeeding.

Special instructions

Spiriva Respimat - bronchodilator, which is prescribed 1 time per day for maintenance therapy. The drug is not intended for the initial treatment of an acute attack of bronchospasm, that is, for emergency care.
Hypersensitivity reactions may occur after using the p-ra for inhalation Spiriva Respimat.
Respiriva Respimat is used with caution in patients with angle-closure glaucoma, prostatic hyperplasia, or bladder neck obstruction.
The use of inhaled drugs may cause bronchospasm caused by their conduct.
There is an increased risk of death in patients with heart rhythm disorders. The relationship of cardiac arrhythmia with death is questionable, in addition, the causal relationship with tiotropium Respimat is not established. The use of Spiriva Respimat, mainly excreted by the kidneys, should be carried out under medical supervision in patients with moderate to severe renal insufficiency (creatinine clearance Patients should be instructed on the correct use of Spiriv Respimat. The solution or aerosol in the eye is unacceptable. Signs of angle-closure glaucoma may pain or discomfort in the eyes, blurred vision, the appearance of a halo or colored spots before the eyes in combination with redness of the eye in the form of conjunctival hyperemia tivy or cornea. If you experience these symptoms in any combination should immediately seek specialized medical attention. Treatment for eye drops that cause constriction of the pupil, is not considered effective.
Spiriva cartridges should be used only with Respimat inhaler.
During pregnancy and breastfeeding. The drug should not be used during pregnancy and lactation without assessing the ratio of the expected benefits and the possible risk to the fetus or child.
Children. The drug Spiriva Respimat not recommended for use in children due to lack of data regarding efficacy and safety.
The ability to influence the reaction rate when driving and working with other mechanisms. For the period of treatment should refrain from driving and working with other mechanisms, given the possibility of dizziness or blurred vision.

Overdosage

The use of the drug Spiriva Respimat in high doses can cause anticholinergic signs and symptoms: dryness of the mucous membranes of the mouth / throat and nasal cavity with a dose-dependent frequency, a decrease in salivary secretions.
Acute intoxication due to accidental oral intake of p-ra tiotropia for inhalations from the cartridge is unlikely due to low bioavailability when administered orally.